MSLN and triple-negative breast carcinoma: Exploiting the high but independent expression of MSLN and NKG2D ligands in triple-negative breast cancer, Saliu et al. designed a novel CAR-T cell that not only targets MSLN but also autonomously secretes bispecific T cell engagers (BiTE) targeting NKG2D ligands.